Western Asset Corporate Loan Fund Inc. (TLI) At $10.46 Forms Bottom; 9 Bullish Analysts Covering Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Logo

Among 11 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Akebia Therapeutics Inc had 25 analyst reports since August 13, 2015 according to SRatingsIntel. On Monday, July 10 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock has “Buy” rating by BTIG Research on Thursday, December 7. Brean Capital maintained the stock with “Buy” rating in Thursday, August 13 report. The rating was maintained by Needham with “Buy” on Tuesday, December 15. The firm has “Buy” rating by Aegis Capital given on Tuesday, November 15. The firm has “Equal Weight” rating by Morgan Stanley given on Thursday, August 13. The rating was maintained by H.C. Wainwright on Tuesday, March 15 with “Buy”. The firm has “Overweight” rating by Morgan Stanley given on Wednesday, September 9. Aegis Capital maintained the shares of AKBA in report on Friday, June 30 with “Buy” rating. Credit Suisse initiated the shares of AKBA in report on Thursday, January 21 with “Neutral” rating. See Akebia Therapeutics, Inc. (NASDAQ:AKBA) latest ratings:

07/03/2018 Broker: Mizuho Rating: Buy New Target: $24.0 Maintain
18/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Initiate
07/12/2017 Broker: BTIG Research Rating: Buy New Target: $30.0 Initiate

Western Asset Corporate Loan Fund Inc. (TLI) formed multiple bottom with $9.62 target or 8.00% below today’s $10.46 share price. Western Asset Corporate Loan Fund Inc. (TLI) has $103.96M valuation. The stock decreased 0.10% or $0.01 during the last trading session, reaching $10.46. About 13,243 shares traded. Western Asset Corporate Loan Fund Inc. (NYSE:TLI) has declined 9.71% since May 7, 2017 and is downtrending. It has underperformed by 21.26% the S&P500.

Since February 15, 2018, it had 0 insider buys, and 1 insider sale for $14,620 activity. Shares for $14,620 were sold by Nash Duane.

Investors sentiment decreased to 1.63 in Q4 2017. Its down 0.60, from 2.23 in 2017Q3. It dived, as 15 investors sold Akebia Therapeutics, Inc. shares while 28 reduced holdings. 26 funds opened positions while 44 raised stakes. 30.27 million shares or 5.16% more from 28.78 million shares in 2017Q3 were reported. Marshall Wace Ltd Liability Partnership holds 0.13% or 204,196 shares in its portfolio. 3.91 million were reported by Blackrock Incorporated. Lpl Fincl Ltd Liability Company accumulated 23,559 shares or 0% of the stock. State Common Retirement Fund holds 52,670 shares or 0% of its portfolio. California Employees Retirement System reported 61,000 shares or 0% of all its holdings. First Manhattan has 565,066 shares for 0.05% of their portfolio. State Of Wisconsin Invest Board holds 26,000 shares or 0% of its portfolio. Acadian Asset Ltd holds 625,167 shares. Jacobs Levy Equity Management reported 0.01% stake. Secor Cap Ltd Partnership holds 0.03% in Akebia Therapeutics, Inc. (NASDAQ:AKBA) or 48,435 shares. Piermont Capital Mgmt Inc reported 0.06% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Numeric Investors Limited Com holds 218,219 shares. Cwm Ltd Liability accumulated 31 shares. Deutsche Bank & Trust Ag invested in 161,640 shares or 0% of the stock. Hancock Holding Com holds 0.04% or 66,900 shares.

The stock increased 3.83% or $0.35 during the last trading session, reaching $9.5. About 239,686 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has risen 5.85% since May 7, 2017 and is uptrending. It has underperformed by 5.70% the S&P500.

Another recent and important Akebia Therapeutics, Inc. (NASDAQ:AKBA) news was published by Globenewswire.com which published an article titled: “Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics …” on April 09, 2018.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Chart